NO20025375L - Fremgangsmåte for behandling og midler som er nyttige for behandlingen - Google Patents

Fremgangsmåte for behandling og midler som er nyttige for behandlingen

Info

Publication number
NO20025375L
NO20025375L NO20025375A NO20025375A NO20025375L NO 20025375 L NO20025375 L NO 20025375L NO 20025375 A NO20025375 A NO 20025375A NO 20025375 A NO20025375 A NO 20025375A NO 20025375 L NO20025375 L NO 20025375L
Authority
NO
Norway
Prior art keywords
treatment
cancers
agents useful
growth
present
Prior art date
Application number
NO20025375A
Other languages
English (en)
Other versions
NO20025375D0 (no
Inventor
Mathew Vadas
Jennifer Gamble
Pu Xia
Lijun Wang
Original Assignee
Medvet Science Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medvet Science Pty Ltd filed Critical Medvet Science Pty Ltd
Publication of NO20025375D0 publication Critical patent/NO20025375D0/no
Publication of NO20025375L publication Critical patent/NO20025375L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO20025375A 2000-05-11 2002-11-08 Fremgangsmåte for behandling og midler som er nyttige for behandlingen NO20025375L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPQ7447A AUPQ744700A0 (en) 2000-05-11 2000-05-11 A method of treatment and agents useful for same
PCT/AU2001/000539 WO2001085953A1 (en) 2000-05-11 2001-05-11 Sphingosine kinase and uses thereof

Publications (2)

Publication Number Publication Date
NO20025375D0 NO20025375D0 (no) 2002-11-08
NO20025375L true NO20025375L (no) 2003-01-07

Family

ID=3821526

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20025375A NO20025375L (no) 2000-05-11 2002-11-08 Fremgangsmåte for behandling og midler som er nyttige for behandlingen

Country Status (17)

Country Link
US (1) US20040014635A1 (no)
EP (1) EP1290182B1 (no)
JP (1) JP2003532423A (no)
CN (1) CN1436241A (no)
AT (1) ATE492276T1 (no)
AU (3) AUPQ744700A0 (no)
BR (1) BR0110759A (no)
CA (1) CA2408196A1 (no)
DE (1) DE60143697D1 (no)
HK (1) HK1054409A1 (no)
IL (1) IL152672A0 (no)
MX (1) MXPA02011112A (no)
NO (1) NO20025375L (no)
NZ (1) NZ543272A (no)
RU (1) RU2326690C2 (no)
WO (1) WO2001085953A1 (no)
ZA (1) ZA200209066B (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6423527B1 (en) 1997-09-29 2002-07-23 Children's Hospital Medical Center Of Northern California Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor
WO2002051439A2 (en) 2000-12-22 2002-07-04 Medlyte, Inc. Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor
US7674580B2 (en) 2002-01-17 2010-03-09 Children's Hospital & Research Center At Oakland Compositions and methods for the modulation of sphingolipid metabolism and/or signaling
EP1517989B1 (en) * 2002-01-17 2009-07-15 Children's Hospital & Research Center at Oakland Method for the diagnosing of sphingolipid metabolism
EP1499343A4 (en) * 2002-03-28 2005-12-28 Medvet Science Pty Ltd METHOD FOR MODULATING CELL ACTIVITY
WO2004035786A1 (en) * 2002-10-14 2004-04-29 Medvet Science Pty. Ltd. A method of modulating epithelial cell activity by modulating the functional levels of sphingosine kinase
EP1570081A4 (en) * 2002-11-19 2006-05-31 Amgen Inc AMPLIFIED GENES INVOLVED IN CANCER
MXPA06014888A (es) * 2004-06-15 2007-03-21 Medvet Science Pty Ltd Metodos para modular actividad celular que involucra esfingosina cinasa y agentes para los mismos, y variantes de esfingosina cinasa.
SI1812797T1 (sl) * 2004-10-28 2013-06-28 Lpath, Inc. Pripravki in metode zdravljenja ter preprečevanja hiperprolifetarivnih bolezni
US8324237B2 (en) * 2005-05-20 2012-12-04 Smith Charles D Methods for the treatment and prevention of inflammatory diseases
US20060270631A1 (en) * 2005-05-26 2006-11-30 Smith Charles D Methods for the treatment and prevention of angiogenic diseases
CA2612640A1 (en) * 2005-06-21 2006-12-28 Medvet Science Pty. Ltd. Modulation of egfr signalling by modulation of sphingosine kinase signalling
EP1910524A4 (en) * 2005-06-21 2009-04-01 Medvet Science Pty Ltd MODULATION OF SPHINGOSINKINASE SIGNALING
US9274130B2 (en) 2006-05-31 2016-03-01 Lpath, Inc. Prevention and treatment of pain using antibodies to lysophosphatidic acid
US9274129B2 (en) 2006-05-31 2016-03-01 Lpath, Inc. Methods and reagents for detecting bioactive lipids
JP5795833B2 (ja) 2006-10-27 2015-10-14 エルパス・インコーポレイテッドＬｐａｔｈ， Ｉｎｃ． スフィンゴシン−１−リン酸と結合させるための組成物および方法
US8871202B2 (en) 2008-10-24 2014-10-28 Lpath, Inc. Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
WO2019182191A1 (ko) 2018-03-21 2019-09-26 경북대학교 산학협력단 C0x2 아세틸화제를 유효성분으로 포함하는 퇴행성 신경질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583160A (en) * 1989-02-03 1996-12-10 The Biomembrane Institute Methylsphingosine used to treat apoptosis
US5068175A (en) * 1989-05-26 1991-11-26 Board Of Regents, The University Of Texas Sysem Method of detecting ras oncogene related malignancies
JPH10182627A (ja) * 1996-12-20 1998-07-07 Sankyo Co Ltd 新規化合物Ｓ−１５１８３ａ及びＳ−１５１８３ｂ
US6649362B2 (en) * 1997-09-08 2003-11-18 Medvet Science Pty. Ltd. Screening method for an agent having an effect on a sphingosine kinase signaling pathway
AUPO900297A0 (en) * 1997-09-08 1997-10-02 Medvet Science Pty. Ltd. A method of modulating cellular activity
AU4097999A (en) * 1998-05-26 1999-12-13 Sarah Spiegel Sphingosine kinase, cloning, expression and methods of use
CA2335941C (en) * 1998-06-29 2011-03-22 Barry James Maurer Treatment of hyperproliferative disorders
EP1192247B9 (en) * 1999-05-13 2007-10-31 Johnson & Johnson Pharmaceutical Research and Development LLC Sphingosine kinase enzyme
MXPA02004294A (es) * 1999-10-28 2002-10-31 Warner Lambert Co Gen de esfingosina cinasa de humano.
US6830916B2 (en) * 2000-03-02 2004-12-14 Sarah Spiegel Sphingosine kinase, cloning, expression and methods of use
MXPA02009781A (es) * 2000-04-03 2004-09-06 Sankyo Co Isoformas de esfingosina cinasa tipo 2 de mamifero, clonacion, expresion y metodos de uso de las mismas.
WO2004035786A1 (en) * 2002-10-14 2004-04-29 Medvet Science Pty. Ltd. A method of modulating epithelial cell activity by modulating the functional levels of sphingosine kinase

Also Published As

Publication number Publication date
CN1436241A (zh) 2003-08-13
EP1290182A1 (en) 2003-03-12
MXPA02011112A (es) 2004-08-19
WO2001085953A1 (en) 2001-11-15
EP1290182B1 (en) 2010-12-22
BR0110759A (pt) 2003-05-06
AU2001256001B2 (en) 2007-03-15
JP2003532423A (ja) 2003-11-05
DE60143697D1 (de) 2011-02-03
AU5600101A (en) 2001-11-20
ZA200209066B (en) 2004-04-07
US20040014635A1 (en) 2004-01-22
EP1290182A4 (en) 2006-01-11
IL152672A0 (en) 2003-06-24
RU2326690C2 (ru) 2008-06-20
AUPQ744700A0 (en) 2000-06-01
CA2408196A1 (en) 2001-11-15
HK1054409A1 (zh) 2003-11-28
NZ543272A (en) 2009-04-30
ATE492276T1 (de) 2011-01-15
NO20025375D0 (no) 2002-11-08

Similar Documents

Publication Publication Date Title
NO20025375D0 (no) FremgangsmÕte for behandling og midler som er nyttige for behandlingen
GB0318438D0 (en) Early entry
GT199900019A (es) Formulas farmaceuticamente estables de solucion de oxaliplatino.
SG148864A1 (en) Methods of treating cancer and related methods
PL341112A1 (en) Methods of providing postmenopausal treatment to female patients using very low doses of oestrogen
MY112949A (en) Benzo-thiaphene estrogen agonists to treat prostatic hyperplasia
AU6769801A (en) Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them
DE60233261D1 (de) Inhibitoren von humanem adam-10
DE60025905D1 (de) In vitro methode zur synchronisation von oozytenreifung
IL150060A0 (en) Novel purines
SI1532131T1 (sl) Motilidne spojine
DE60218153D1 (de) Verwendung von proteasom-inhibitoren zur behandlung des trockenen auges
HUP0102967A2 (hu) Eljárás organoszilil-alkilpoliszulfánok előállítására
TR200002203T2 (tr) Lemfotoksin (LT) sentezlenme yolunun inhibitörleri kullanılarak foliküler lemfomaların tedavisi.
MY138550A (en) Method for synthesis of perindopril and its pharmaceutically acceptable salts
MY136938A (en) New process for the synthesis of perindopril and its pharmaceutically acceptable salts
MY139159A (en) Method for synthesis of perindopril and its pharmaceutically acceptable salts
DE59902666D1 (de) Edelfosin zur behandlung von hirntumoren
MY135359A (en) New process for the synthesis of perindopril and pharmaceutically acceptable salts thereof
AU2002220712A1 (en) Stem cells, method for expansion in vitro and use thereof
MY136638A (en) New process for the synthesis of perindopril and its pharmaceutically acceptable salts
EA200200034A1 (ru) Способ лечения остеохондроза позвоночника
MY139443A (en) Method for synthesis of perindopril and its pharmaceutically acceptable salts
MY149837A (en) New process for the synthesis of perindopril and pharmaceutically acceptable salts thereof
PT1406512E (pt) Tratamento de substratos lenhocelulósicos com ozono

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application